Article
TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Blood cancer journal - 31 Jul 2015
Hou H-A, Chou W-C, Kuo Y-Y, Liu C-Y, Lin L-I, Tseng M-H, Chiang Y-C, Liu M-C, Liu C-W, Tang J-L, Yao M, Li C-C, Huang S-Y, Ko B-S, Hsu S-C, Chen C-Y, Lin C-T, Wu S-J, Tsay W, Chen Y-C, Tien H-F
Abstract excerpt
The TP53 mutation is frequently detected in acute myeloid leukemia (AML) patients with complex karyotype (CK), but the stability of this mutation during the clinical course remains unclear. In this study, TP53 mutations were identified in 7% of 500 patients with de novo AML and 58.8% of patients with CK. TP53 mutations were closely associated with older age, lower white blood cell (WBC) and platelet counts, FAB...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.